An American, multicenter, Phase I/II trial is currently ongoing, recruiting 220 patients with HER-2-positive tumors, including BC, to evaluate the safety, tolerability, and clinical activity of HER2-specific dual-switch CAR-T cells, BPX-603, administered with rimiducid. This evidence concerns the gene ERBB2 and breast cancer.